Pharmacokinetics and safety of ubrogepant when coadministered with calcitonin gene‒related peptide‐targeted monoclonal antibody migraine preventives in participants with migraine: A randomized phase 1b drug–drug interaction study-Reference-Cited by-同舟云学术

Pharmacokinetics and safety of ubrogepant when coadministered with calcitonin gene‒related peptide‐targeted monoclonal antibody migraine preventives in participants with migraine: A randomized phase 1b drug–drug interaction study

Published:2021-04 Issue:4 Volume:61 Page:642-652
ISSN:0017-8748
Container-title:Headache: The Journal of Head and Face Pain
language:en
Short-container-title:Headache: The Journal of Head and Face Pain

Author:

Jakate Abhijeet¹,Blumenfeld Andrew M.²,Boinpally Ramesh¹,Butler Matthew¹,Borbridge Lisa³,Contreras‐De Lama Janette¹,McGeeney Danielle¹,Periclou Antonia¹,Lipton Richard B.⁴

Affiliation:

1. Clinical Pharmacology AbbVie Madison NJ USA

2. Headache Center of Southern California Carlsbad CA USA

3. Bioanalysis, Non‐clinical and Translational Sciences AbbVie Irvine CA USA

4. The Saul R. Korey Department of Neurology, Department of Psychiatry and Behaviorial Sciences, Department of Epidemiology & Population Health Albert Einstein College of Medicine Bronx NY USA

Funder

AbbVie

Publisher

Wiley

Subject

Neurology (clinical),Neurology

Link

https://onlinelibrary.wiley.com/doi/pdf/10.1111/head.14095

Reference42 articles.

1. Headache Classification Committee of the International Headache Society (IHS) The International Classification of Headache Disorders, 3rd edition

2. Pathophysiology of Migraine

3. The American Headache Society Position Statement On Integrating New Migraine Treatments Into Clinical Practice